US 12,005,124
Application 18/492,894 · Granted Jun 11, 2024
Muscle targeting complexes and uses thereof for treating dystrophinopathies
Estimated expiration
August 2, 2039
12y 257d remaining
Earliest effective filing
Aug 2, 2019
+ 20 years
Aug 2, 2039
PTA +0d
Aug 2, 2039
TD cap (US 11,168,141)
Aug 2, 2039
Final
Aug 2, 2039
- Earliest effective filing
- Aug 2, 2019
- + 20 years
- Aug 2, 2039
- PTA +0d
- Aug 2, 2039
- TD cap (US 11,168,141)
- Aug 2, 2039
- Final
- Aug 2, 2039
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- October 24, 2023
- Earliest effective filing
- August 2, 2019
- Issue date
- June 11, 2024
- PTA
- 0 days
- Base expiry (before PTA)
- August 2, 2039
August 2, 2019 + 20 years = August 2, 2039
- Continuation of application 18/181,623, filed Mar 10, 2023, issued as US 11,833,217
- Continuation of application 17/930,522, filed Sep 8, 2022, issued as US 11,633,496
- Continuation of application 17/751,875, filed May 24, 2022, issued as US 11,497,815
- Continuation of application 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
- Continuation of application 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
- Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
- Continuation of application 17/265,024, filed Feb 1, 2021
- National stage entry of application PCTUS2019044949, filed Aug 2, 2019
- National stage entry of application PCTUS2019044949, filed Aug 2, 2019
- Continuation of application 17/265,024, filed Feb 1, 2021
- National stage entry of application PCTUS2019044949, filed Aug 2, 2019
- Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
- Continuation of application 17/265,024, filed Feb 1, 2021
- National stage entry of application PCTUS2019044949, filed Aug 2, 2019
- Continuation of application 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
- Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
- Continuation of application 17/265,024, filed Feb 1, 2021
- National stage entry of application PCTUS2019044949, filed Aug 2, 2019
- Continuation of application 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
- Continuation of application 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
- Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
- Continuation of application 17/265,024, filed Feb 1, 2021
- National stage entry of application PCTUS2019044949, filed Aug 2, 2019
- Continuation of application 17/751,875, filed May 24, 2022, issued as US 11,497,815
- Continuation of application 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
- Continuation of application 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
- Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
- Continuation of application 17/265,024, filed Feb 1, 2021
- National stage entry of application PCTUS2019044949, filed Aug 2, 2019
- Continuation of application 17/930,522, filed Sep 8, 2022, issued as US 11,633,496
- Continuation of application 17/751,875, filed May 24, 2022, issued as US 11,497,815
- Continuation of application 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
- Continuation of application 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
- Continuation of application 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
- Continuation of application 17/265,024, filed Feb 1, 2021
- National stage entry of application PCTUS2019044949, filed Aug 2, 2019
- PRO62/714,031 — Provisional — not used for base term
- PRO62/855,766 — Provisional — not used for base term
- PRO62/855,766 — Provisional — not used for base term
- PRO62/714,031 — Provisional — not used for base term
- PRO62/855,766 — Provisional — not used for base term
- PRO62/714,031 — Provisional — not used for base term
- PRO62/855,766 — Provisional — not used for base term
- PRO62/714,031 — Provisional — not used for base term
- PRO62/855,766 — Provisional — not used for base term
- PRO62/714,031 — Provisional — not used for base term
- PRO62/855,766 — Provisional — not used for base term
- PRO62/714,031 — Provisional — not used for base term
- PRO62/855,766 — Provisional — not used for base term
- PRO62/714,031 — Provisional — not used for base term
- PRO62/855,766 — Provisional — not used for base term
- PRO62/714,031 — Provisional — not used for base term
- PRO62/855,766 — Provisional — not used for base term
- PRO62/714,031 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to August 2, 2039 (earliest expiring referenced patent: US 11,168,141)
US 11,168,141· Application 17/205,151Capping patent
Muscle targeting complexes and uses thereof for treating dystrophinopathies
- Filing date
- Mar 18, 2021
- Earliest effective filing
- Aug 2, 2019
- Issue date
- Nov 9, 2021
- PTA
- 0 days
- Calculated expiration
- Aug 2, 2039
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Aug 2, 2019 + 20y = Aug 2, 2039
US 11,248,056· Application 17/501,066
Muscle targeting complexes and uses thereof for treating dystrophinopathies
- Filing date
- Oct 14, 2021
- Earliest effective filing
- Aug 2, 2019
- Issue date
- Feb 15, 2022
- PTA
- 0 days
- Calculated expiration
- Aug 2, 2039
Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Aug 2, 2019 + 20y = Aug 2, 2039
US 11,369,689· Application 17/580,844
Muscle targeting complexes and uses thereof for treating dystrophinopathies
- Filing date
- Jan 21, 2022
- Earliest effective filing
- Aug 2, 2019
- Issue date
- Jun 28, 2022
- PTA
- 0 days
- Calculated expiration
- Aug 2, 2039
Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Aug 2, 2019 + 20y = Aug 2, 2039
US 11,497,815· Application 17/751,875
Muscle targeting complexes and uses thereof for treating dystrophinopathies
- Filing date
- May 24, 2022
- Earliest effective filing
- Aug 2, 2019
- Issue date
- Nov 15, 2022
- PTA
- 0 days
- Calculated expiration
- Aug 2, 2039
Continuation of 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Aug 2, 2019 + 20y = Aug 2, 2039
US 11,633,496· Application 17/930,522
Muscle targeting complexes and uses thereof for treating dystrophinopathies
- Filing date
- Sep 8, 2022
- Earliest effective filing
- Aug 2, 2019
- Issue date
- Apr 25, 2023
- PTA
- 0 days
- Calculated expiration
- Aug 2, 2039
Continuation of 17/751,875, filed May 24, 2022, issued as US 11,497,815
Continuation of 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Continuation of 17/580,844, filed Jan 21, 2022, issued as US 11,369,689
Continuation of 17/501,066, filed Oct 14, 2021, issued as US 11,248,056
Continuation of 17/205,151, filed Mar 18, 2021, issued as US 11,168,141
Continuation of 17/265,024, filed Feb 1, 2021
National stage entry of PCTUS2019044949, filed Aug 2, 2019
Aug 2, 2019 + 20y = Aug 2, 2039
Notes (1)
- [TD_REFS_TRUNCATED] Found 19 TD references; resolving first 5 only
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
You have the date. Your AI can have the file.
Application 18/492,894 · US 12,005,124
PatentReply compiles the prosecution history behind US 12,005,124: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new published application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12005124Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.